528 related articles for article (PubMed ID: 12733144)
1. Avascular necrosis in long-term survivors after allogeneic or autologous stem cell transplantation: a single center experience and a review.
Tauchmanovà L; De Rosa G; Serio B; Fazioli F; Mainolfi C; Lombardi G; Colao A; Salvatore M; Rotoli B; Selleri C
Cancer; 2003 May; 97(10):2453-61. PubMed ID: 12733144
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms of bone loss following allogeneic and autologous hemopoietic stem cell transplantation.
Ebeling PR; Thomas DM; Erbas B; Hopper JL; Szer J; Grigg AP
J Bone Miner Res; 1999 Mar; 14(3):342-50. PubMed ID: 10027899
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma.
Kuruvilla J; Shepherd JD; Sutherland HJ; Nevill TJ; Nitta J; Le A; Forrest DL; Hogge DE; Lavoie JC; Nantel SH; Toze CL; Smith CA; Barnett MJ; Song KW
Biol Blood Marrow Transplant; 2007 Aug; 13(8):925-31. PubMed ID: 17640596
[TBL] [Abstract][Full Text] [Related]
4. Avascular necrosis of bone following allogeneic stem cell transplantation: MR screening and therapeutic options.
Wiesmann A; Pereira P; Böhm P; Faul C; Kanz L; Einsele H
Bone Marrow Transplant; 1998 Sep; 22(6):565-9. PubMed ID: 9758344
[TBL] [Abstract][Full Text] [Related]
5. Hematopoietic stem cell graft manipulation as a mechanism of immunotherapy.
Talmadge JE
Int Immunopharmacol; 2003 Aug; 3(8):1121-43. PubMed ID: 12860168
[TBL] [Abstract][Full Text] [Related]
6. Osteonecrosis after allogeneic stem cell transplantation in childhood. A case-control study in Italy.
Faraci M; Calevo MG; Lanino E; Caruso S; Messina C; Favr C; Iori A; Santaron S; Bonanomi S; Rondelli R; Dini G; Haupt R;
Haematologica; 2006 Aug; 91(8):1096-9. PubMed ID: 16885050
[TBL] [Abstract][Full Text] [Related]
7. Avascular necrosis of femoral and/or humeral heads in multiple myeloma: results of a prospective study of patients treated with dexamethasone-based regimens and high-dose chemotherapy.
Talamo G; Angtuaco E; Walker RC; Dong L; Miceli MH; Zangari M; Tricot G; Barlogie B; Anaissie E
J Clin Oncol; 2005 Aug; 23(22):5217-23. PubMed ID: 15955903
[TBL] [Abstract][Full Text] [Related]
8. Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia.
Anagnostopoulos A; Hari PN; Pérez WS; Ballen K; Bashey A; Bredeson CN; Freytes CO; Gale RP; Gertz MA; Gibson J; Goldschmidt H; Lazarus HM; McCarthy PL; Reece DE; Vesole DH; Giralt SA
Biol Blood Marrow Transplant; 2006 Aug; 12(8):845-54. PubMed ID: 16864055
[TBL] [Abstract][Full Text] [Related]
9. Avascular osteonecrosis after renal transplantation.
Hedri H; Cherif M; Zouaghi K; Abderrahim E; Goucha R; Ben Hamida F; Ben Abdallah T; Elyounsi F; Ben Moussa F; Ben Maiz H; Kheder A
Transplant Proc; 2007 May; 39(4):1036-8. PubMed ID: 17524885
[TBL] [Abstract][Full Text] [Related]
10. Long-lasting bone damage detected by dual-energy x-ray absorptiometry, phalangeal osteosonogrammetry, and in vitro growth of marrow stromal cells after allogeneic stem cell transplantation.
Tauchmanovà L; Serio B; Del Puente A; Risitano AM; Esposito A; De Rosa G; Lombardi G; Colao A; Rotoli B; Selleri C
J Clin Endocrinol Metab; 2002 Nov; 87(11):5058-65. PubMed ID: 12414872
[TBL] [Abstract][Full Text] [Related]
11. Role of pretransplant interferon-alpha(IFN) treatment in the outcome of stem cell transplantation (SCT) from related donors in chronic myelogenous leukemia (CML): results from three Turkish transplant centers.
Beksac M; Celebi H; Sargín D; Yalcin A; Topcuoglu P; Kalayoglu-Besisik S; Beyan C; Arslan O; Ozcan M; Gurman G; Ilhan O; Akan H
Bone Marrow Transplant; 2003 May; 31(10):897-904. PubMed ID: 12748666
[TBL] [Abstract][Full Text] [Related]
12. Bone mineral density and osteonecrosis in survivors of childhood allogeneic bone marrow transplantation.
Kaste SC; Shidler TJ; Tong X; Srivastava DK; Rochester R; Hudson MM; Shearer PD; Hale GA
Bone Marrow Transplant; 2004 Feb; 33(4):435-41. PubMed ID: 14716354
[TBL] [Abstract][Full Text] [Related]
13. Low pretransplant bone-mineral density and rapid bone loss do not increase risk for avascular osteonecrosis after allogeneic hematopoietic stem cell transplantation.
Schulte CM; Beelen DW
Transplantation; 2005 Jun; 79(12):1748-55. PubMed ID: 15973180
[TBL] [Abstract][Full Text] [Related]
14. Chronic graft-versus-host disease after allogeneic stem cell transplantation: challenges in prevention, science, and supportive care.
Joseph RW; Couriel DR; Komanduri KV
J Support Oncol; 2008; 6(8):361-72. PubMed ID: 19149321
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial.
Ribera JM; Oriol A; Bethencourt C; Parody R; Hernández-Rivas JM; Moreno MJ; del Potro E; Torm M; Rivas C; Besalduch J; Sanz MA; Ortega JJ;
Haematologica; 2005 Oct; 90(10):1346-56. PubMed ID: 16219571
[TBL] [Abstract][Full Text] [Related]
16. Corticosteroid dose as a risk factor for avascular necrosis of the bone after hematopoietic cell transplantation.
McAvoy S; Baker KS; Mulrooney D; Blaes A; Arora M; Burns LJ; Majhail NS
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1231-6. PubMed ID: 20302963
[TBL] [Abstract][Full Text] [Related]
17. [Influence of graft-versus-host disease on long-term survival of 26 patients with hematologic malignancies after transplantation].
Lin Q; Dong M; Wang QM; Wen JY; Wu XY
Ai Zheng; 2006 Oct; 25(10):1261-5. PubMed ID: 17059772
[TBL] [Abstract][Full Text] [Related]
18. The impact of acute and chronic graft-versus-host disease on normal and malignant B-lymphoid precursors after allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia.
Sánchez-García J; Serrano J; Gómez P; Martínez F; Martín C; Román-Gómez J; Rodríguez A; Herrera C; García JM; Alvarez MA; Torres A
Haematologica; 2006 Mar; 91(3):340-7. PubMed ID: 16531257
[TBL] [Abstract][Full Text] [Related]
19. Early complete donor hematopoietic chimerism in peripheral blood indicates the risk of extensive graft-versus-host disease.
Balon J; Hałaburda K; Bieniaszewska M; Reichert M; Bieniaszewski L; Piekarska A; Pawłowski R; Hellmann A
Bone Marrow Transplant; 2005 Jun; 35(11):1083-8. PubMed ID: 15821766
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation.
Pavletic SZ; Smith LM; Bishop MR; Lynch JC; Tarantolo SR; Vose JM; Bierman PJ; Hadi A; Armitage JO; Kessinger A
Am J Hematol; 2005 Apr; 78(4):265-74. PubMed ID: 15795914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
